Natco Pharma Limited has informed the Exchange regarding a press release dated April 10, 2021, titled "NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA ��) ANDA in the US market".
Press Release Apr 10 2021
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from NATCO Pharma
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
- Press Release Mar 15 2021
- Press Release Mar 08 2021
- NATCO Pharma launches Brivaracetam tablets, in India, for treatment of epilepsy
- Press Release Feb 26 2021
Later from NATCO Pharma
- NATCO Pharma receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA) ANDA in the US market
- Press Release Apr 26 2021
- Press Release May 03 2021
- Press Release May 17 2021
- Press Release May 21 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma